Crizanlizuamb + Standard of Care
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease (SCD)
Conditions
Sickle Cell Disease (SCD)
Trial Timeline
Dec 10, 2019 → Mar 20, 2023
NCT ID
NCT04053764About Crizanlizuamb + Standard of Care
Crizanlizuamb + Standard of Care is a phase 2 stage product being developed by Novartis for Sickle Cell Disease (SCD). The current trial status is completed. This product is registered under clinical trial identifier NCT04053764. Target conditions include Sickle Cell Disease (SCD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04053764 | Phase 2 | Completed |
Competing Products
20 competing products in Sickle Cell Disease (SCD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prasugrel + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 33 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel | Daiichi Sankyo | Phase 2 | 52 |
| Lexiscan | Astellas Pharma | Phase 1 | 33 |
| Placebo + Dalteparin | Eisai | Phase 2 | 52 |
| tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT]) | Eli Lilly | Phase 1 | 33 |
| Lidocaine Iv + Placebo | Johnson & Johnson | Phase 2 | 52 |
| ICA-17043 | Johnson & Johnson | Phase 3 | 77 |
| Ticagrelor | AstraZeneca | Phase 1 | 33 |
| Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet) | AstraZeneca | Phase 1 | 33 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Placebo | AstraZeneca | Phase 3 | 77 |
| Brilinta + Placebo | AstraZeneca | Phase 3 | 77 |
| Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b | AstraZeneca | Phase 2 | 52 |
| vorinostat | Merck | Phase 2 | 52 |
| Crizanlizumab + Placebo | Novartis | Phase 3 | 77 |
| Crizanlizumab | Novartis | Approved | 85 |
| Hydroxyurea | Novartis | Phase 3 | 77 |